3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
214
Thoracic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Colorectal Neoplasms
4588
Pancreatic Neoplasms
2837
Carcinoma, Hepatocellular
2473
Stomach Neoplasms
2325
Colonic Neoplasms
1790
Rectal Neoplasms
1714
Esophageal Neoplasms
1373
Liver Neoplasms
920
Neoplasms
913
Breast Neoplasms
836
Neoplasm Metastasis
761
Carcinoma, Non-Small-Cell Lung
702
Cholangiocarcinoma
581
Lung Neoplasms
555
Ovarian Neoplasms
533
Esophageal Squamous Cell Carcinoma
510
Gastrointestinal Neoplasms
494
Melanoma
381
Prostatic Neoplasms
371
Biliary Tract Neoplasms
370
Head and Neck Neoplasms
303
Uterine Cervical Neoplasms
286
Carcinoma, Renal Cell
282
Adenocarcinoma Of Esophagus
273
Sarcoma
263
Squamous Cell Carcinoma of Head and Neck
262
Gastrointestinal Stromal Tumors
251
Endometrial Neoplasms
233
Urinary Bladder Neoplasms
226
Gallbladder Neoplasms
223
Interventions
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Non-Muscle Invasive Bladder Neoplasms
×
Gastrointestinal
×
Clear all
NCT06448364
2024-11-06
LTbR
Pfizer
Phase 1
Terminated
4 enrolled